Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Colon Cancer

May 12, 2021

Advances in the Treatment of Metastatic Colon Cancer
The addition of new therapies based on the results of biomarker testing has substantially expanded treatment options for metastatic colorectal cancer (mCRC) in recent years, raising new questions about how to select the most appropriate therapy for a specific patient based on their biomarker testing results and how to optimally sequence these therapies. Education is needed to help guide clinicians on appropriate biomarker testing for patients with mCRC and how the results of these tests can aid in treatment decision-making in this rapidly evolving landscape. Optimal treatment strategies can maximize benefits while minimizing harms, giving patients with mCRC the best quality and quantity of life possible.

Target Audience

This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Describe considerations for biomarker testing in patients with metastatic colorectal cancer (mCRC), including interpretation of results and their impact on treatment selection.
  • Compare and contrast recent and emerging targeted therapy options for mCRC and how these new therapies may be incorporated into a treatment plan.
  • Explain results of recent clinical trials of systemic therapies for patients with mCRC.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • AstraZeneca
  • Clovis Oncology, Inc.
  • Daiichi Sankyo, Inc.
  • GlaxoSmithKline
  • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Lilly
  • Novartis
  • Puma Biotechnology
  • Seattle Genetics, Inc.
  • Taiho Oncology, Inc.

This activity is supported by independent educational grants from:

  • Astellas and Pfizer, Inc.
  • Merck  & Co., Inc.

This activity is supported by independent medical education grants from:

  • Bristol Myers Squibb
  • Sanofi Genzyme

This educational activity is supported by medical education grants from:

  • Exelixis, Inc.
  • Karyopharm Therapeutics
Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
04/13/2021
Course expires: 
08/01/2021
Event starts: 
05/12/2021 - 12:00pm
Event ends: 
05/12/2021 - 1:00pm
Cost:
$0.00

Dara L. Aisner, MD, PhD
University of Colorado Cancer Center

Wells A. Messersmith, MD
University of Colorado Cancer Center

 

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). 

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Full disclosure of faculty relationships will be made prior to the activity.

 

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-21-038-L01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1.0 CE contact hour. Activity Code: I00046207; Approval #: 210001575

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Click the Take Course button to register for this live webinar.

This webinar will be presented live one time only on Wednesday, May 12, 2021, from 12:00 – 1:00 PM Eastern Daylight Time (EDT) (UTC -4).  To adjust for other time zones, click here.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing